Stay updated with breaking news from Biocon Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biotechnology major Biocon is recalling 3,665 bottles of antifungal medication in the US market for "failed degradation specifications", according to the US Food and Drug Administration (USFDA).
USFDA noted that the New Jersey-based Biocon Pharma Inc is recalling the affected lot due to ‘Failed Impurities/Degradation Specifications: High Out Of Specification degradation results’.
On Friday, Celgene Corporation filed a complaint in the District of New Jersey. The case was filed against Biocon Pharma Inc. The action focuses on
Stocks in news: Adani Wilmar, TVS Motors, Castrol India, Biocon, L&T, Minda Industries and more
Stocks in news: ONGC, Bharat Dynamics, ABB India, Biocon, Canara Bank, Ujjivan Financial and more